

Ioannis Kotsianidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1277459/publications.pdf>

Version: 2024-02-01

118
papers

2,508
citations

304743

22
h-index

214800

47
g-index

120
all docs

120
docs citations

120
times ranked

6396
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. <i>Leukemia and Lymphoma</i> , 2022, 63, 729-737.	1.3	2
2	Onionskin-like histiocytes in an HIV late presenter. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, , .	0.5	0
3	Reproductive Failure and Thrombophilia: Not Enough Evidence for a Tight Bond. <i>Acta Haematologica</i> , 2022, 145, 170-175.	1.4	1
4	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	1.3	2
5	Blood and platelet transfusion from a donor with presymptomatic Covid-19. <i>Annals of Hematology</i> , 2021, 100, 2133-2134.	1.8	8
6	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.8	3
7	Upregulated hypoxia inducible factor 1 α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine” data from the Hellenic myelodysplastic syndrome study group. <i>Hematological Oncology</i> , 2021, 39, 231-242.	1.7	1
8	The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. <i>British Journal of Haematology</i> , 2021, 192, 978-987.	2.5	4
9	Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3 α T cells represents a potential antitumor mechanism of azacitidine. <i>Blood Advances</i> , 2021, 5, 129-142.	5.2	7
10	The Calcitriol/Vitamin D Receptor System Regulates Key Immune Signaling Pathways in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 285.	3.7	3
11	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	6.2	2
12	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	1.8	10
13	Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter. <i>Frontiers in Oncology</i> , 2021, 11, 650473.	2.8	16
14	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	3.7	15
15	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	5.2	12
16	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.8	3
17	Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. <i>Frontiers in Oncology</i> , 2021, 11, 801524.	2.8	9
18	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	3.5	35

#	ARTICLE	IF	CITATIONS
19	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 114-121.	0.4	5
20	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	1.0	5
21	The STAT signaling profile at the single cell level reveals novel insights in the association of FOXP3+ T regulatory cells with recurrent spontaneous abortions before and after lymphocyte immunotherapy. <i>Clinical Immunology</i> , 2020, 210, 108261.	3.2	6
22	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	30.7	372
23	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	2.5	9
24	Chemotherapy-induced changes in bronchoalveolar lavage fluid CD4 ⁺ and CD8 ⁺ cells of the opposite lung to the cancer. <i>Scientific Reports</i> , 2020, 10, 19927.	3.3	2
25	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis-stimulating agents. <i>Leukemia Research</i> , 2020, 99, 106472.	0.8	4
26	Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 704-711.	0.4	3
27	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	1.7	3
28	Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity. <i>British Journal of Haematology</i> , 2020, 190, 809-809.	2.5	3
29	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	1.0	2
30	Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of <i>Lactobacillus casei</i> . <i>Cancers</i> , 2020, 12, 368.	3.7	55
31	The effect of transfusion on immune responses in thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 83, 102425.	1.4	3
32	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020, 105, 2516-2523.	3.5	12
33	Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3277-3281.	1.3	2
34	Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 1063-1075.	2.2	3
35	Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019045.	1.3	5
36	DETECTION OF CALR MUTATIONS USING HIGH RESOLUTION MELTING CURVE ANALYSIS (HRM-A); APPLICATION ON A LARGE COHORT OF GREEK ET AND MF PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019009.	1.3	8

#	ARTICLE	IF	CITATIONS
37	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	2.8	6
38	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	1.8	9
39	Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression. <i>Genome Medicine</i> , 2019, 11, 86.	8.2	20
40	Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. <i>Leukemia and Lymphoma</i> , 2019, 60, 1721-1730.	1.3	12
41	Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?. <i>Leukemia and Lymphoma</i> , 2019, 60, 1685-1692.	1.3	5
42	Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine. <i>Blood</i> , 2019, 134, 1721-1721.	1.4	1
43	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 675-675.	1.4	17
44	Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor- κ B Ligand (RANKL). <i>Medical Science Monitor</i> , 2019, 25, 2151-2158.	1.1	14
45	Isothiocyanate-induced Cell Cycle Arrest in a Novel In Vitro Exposure Protocol of Human Malignant Melanoma (A375) Cells. <i>Anticancer Research</i> , 2019, 39, 591-596.	1.1	7
46	Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. <i>ELife</i> , 2019, 8, .	6.0	44
47	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	1.4	0
48	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	1.4	0
49	Molecular Mechanisms of Primary Resistance to Azacytidine in MDS/AML Patients - Data of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5403-5403.	1.4	0
50	Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacytidine: A Retrospective Analysis from the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5417-5417.	1.4	0
51	Functional Calcitriol/Vitamin D Receptor Signaling in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3019-3019.	1.4	0
52	Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 2988-2988.	1.4	0
53	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	4.1	10
54	THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018058.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells. <i>Annals of Biomedical Engineering</i> , 2018, 46, 1975-1987.	2.5	4
56	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.8	0
57	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	1.7	14
58	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. <i>Hematological Oncology</i> , 2018, 36, 645-650.	1.7	6
59	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018, 132, 4357-4357.	1.4	1
60	Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib. <i>Turkish Journal of Haematology</i> , 2018, 35, 147-149.	0.5	2
61	Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death. <i>Blood</i> , 2018, 132, 4385-4385.	1.4	1
62	Longer Duration and Proper Titration of Low Molecular Weight Heparin (LMWH), Are Independent Factors for Successful Pregnancy Outcome. Retrospective Analysis from a Single Center. <i>Blood</i> , 2018, 132, 5065-5065.	1.4	1
63	Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry. <i>Blood</i> , 2018, 132, 3107-3107.	1.4	0
64	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. <i>Blood</i> , 2018, 132, 5463-5463.	1.4	0
65	The Therapeutic Response of Myelodysplastic Syndromes to Azacytidine Is Independent of Endogenous Retroelement Modulation. <i>Blood</i> , 2018, 132, 4349-4349.	1.4	0
66	A retrospective study of azacytidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. <i>International Journal of Hematology</i> , 2017, 105, 184-195.	1.6	4
67	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017, 35, 1591-1597.	1.6	79
68	Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017066.	1.3	4
69	Two potential probiotic lactobacillus strains isolated from olive microbiota exhibit adhesion and anti-proliferative effects in cancer cell lines. <i>Journal of Functional Foods</i> , 2016, 24, 461-471.	3.4	71
70	The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacytidine. <i>Clinical Cancer Research</i> , 2016, 22, 1958-1968.	7.0	16
71	Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1182-1188.	1.3	3
72	Lactobacillus casei Exerts Anti-Proliferative Effects Accompanied by Apoptotic Cell Death and Up-Regulation of TRAIL in Colon Carcinoma Cells. <i>PLoS ONE</i> , 2016, 11, e0147960.	2.5	208

#	ARTICLE	IF	CITATIONS
73	Gradient Infiltration of Neutrophil Extracellular Traps in Colon Cancer and Evidence for Their Involvement in Tumour Growth. <i>PLoS ONE</i> , 2016, 11, e0154484.	2.5	104
74	Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2016, 128, 2004-2004.	1.4	0
75	Adaptive Evolution Coupled with Retrotransposon Exaptation Allowed for the Generation of a Human-Protein-Specific Coding Gene That Promotes Cancer Cell Proliferation and Metastasis in Both Haematological Malignancies and Solid Tumours: The Extraordinary Case of <i>MYEOV</i> Gene. <i>Scientifica</i> , 2015, 2015, 1-10.	1.7	6
76	Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study. <i>Hematology</i> , 2015, 20, 405-409.	1.5	12
77	Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms. <i>Leukemia Research</i> , 2015, 39, 1159-1165.	0.8	7
78	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. <i>Blood</i> , 2015, 126, 1665-1665.	1.4	1
79	Low-Dose Clarithromycin Therapy Modulates Th17 Response In Non-Cystic Fibrosis Bronchiectasis Patients. <i>Lung</i> , 2014, 192, 849-855.	3.3	23
80	Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway. <i>Stem Cells and Development</i> , 2014, 23, 1568-1581.	2.1	48
81	Surface antigen expression in CLL: A new member among the mnesteres for the prognosis of bad risk disease. <i>Leukemia Research</i> , 2014, 38, 423-424.	0.8	0
82	CD1d expression as a prognostic marker for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 320-325.	1.3	16
83	Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience. <i>Leukemia Research</i> , 2014, 38, 161-165.	0.8	4
84	Sequential development of different acute leukemia types in the same patient. <i>Blood</i> , 2014, 124, 2608-2608.	1.4	0
85	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. <i>Hematological Oncology</i> , 2013, 31, 10-17.	1.7	30
86	Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. <i>Leukemia Research</i> , 2013, 37, 889-893.	0.8	13
87	Synchronous BALT Lymphoma and Squamous Cell Carcinoma of the Lung: Coincidence or Linkage?. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-3.	0.3	4
88	Epidural anesthesia followed by epidural analgesia produces less inflammatory response than spinal anesthesia followed by intravenous morphine analgesia in patients with total knee arthroplasty. <i>Medical Science Monitor</i> , 2013, 19, 73-80.	1.1	29
89	Expression Of CD25 Antigen On CD34+ Cells Is An Independent Predictor Of Survival In Late Stage MDS Patients Treated With Azacitidine. <i>Blood</i> , 2013, 122, 1508-1508.	1.4	0
90	Distinct Profile and Epigenetic Modulation Of STAT Signaling In FOXP3+ T Regulatory Cells Among The Various MDS Subtypes. <i>Blood</i> , 2013, 122, 1509-1509.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Statin-Induced Immunomodulation Alters Peripheral Invariant Natural Killer T-cell Prevalence in Hyperlipidemic Patients. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 293-299.	2.6	5
92	Autophagy Mediates the Delivery of Thrombogenic Tissue Factor to Neutrophil Extracellular Traps in Human Sepsis. <i>PLoS ONE</i> , 2012, 7, e45427.	2.5	181
93	Hypomethylating therapy and autoimmunity in MDS: An enigmatic relationship. <i>Leukemia Research</i> , 2012, 36, e90-e92.	0.8	9
94	Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. <i>American Journal of Hematology</i> , 2012, 87, 131-132.	4.1	4
95	The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine. <i>Blood</i> , 2012, 120, 3795-3795.	1.4	0
96	Safety and Efficacy of Azacitidine in Myelodysplastic Syndrome (MDS) Patients with Mild and Moderate Renal Impairment. <i>Blood</i> , 2012, 120, 1716-1716.	1.4	0
97	Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes. <i>Clinical Immunology</i> , 2011, 139, 350-359.	3.2	44
98	Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. <i>Journal of Translational Medicine</i> , 2011, 9, 182.	4.4	61
99	Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. <i>Leukemia Research</i> , 2011, 35, 459-464.	0.8	25
100	Activated Invariant NKT Cells Regulate Osteoclast Development and Function. <i>Journal of Immunology</i> , 2011, 186, 2910-2917.	0.8	33
101	The Diagnostic Value of CD1d Expression in a Large Cohort of Patients With B-Cell Chronic Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2011, 136, 400-408.	0.7	25
102	Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion. <i>American Journal of Hematology</i> , 2010, 85, 146-146.	4.1	12
103	Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma. <i>Blood</i> , 2010, 116, 4049-4049.	1.4	0
104	Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine. <i>Blood</i> , 2010, 116, 2921-2921.	1.4	2
105	Long-Term Effect of Continuous Positive Airway Pressure Therapy on Inflammation Markers of Patients with Obstructive Sleep Apnea Syndrome. <i>Sleep</i> , 2009, , .	1.1	1
106	Global Impairment of CD4 ⁺ CD25 ⁺ FOXP3 ⁺ Regulatory T Cells in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1121-1130.	5.6	196
107	Oxidised low-density lipoprotein and arterial function in β^0 thalassemia major. <i>European Journal of Haematology</i> , 2009, 82, 477-483.	2.2	9
108	Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. <i>Annals of Hematology</i> , 2009, 88, 629-632.	1.8	14

#	ARTICLE	IF	CITATIONS
109	Regulation of multiple myeloma survival and progression by CD1d. <i>Blood</i> , 2009, 113, 2498-2507.	1.4	94
110	In vitro Effects of the Farnesyltransferase Inhibitor Tipifarnib on Myelodysplastic Syndrome Progenitors. <i>Acta Haematologica</i> , 2008, 120, 51-56.	1.4	5
111	Dynamics of Telomere Length and Telomerase Activity in Ph1-Negative Chronic Myeloproliferative Disorders. <i>Blood</i> , 2008, 112, 2789-2789.	1.4	0
112	Leukocyte activation after coronary stenting in patients during the subacute phase of a previous ST-elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2007, 18, 105-110.	0.7	5
113	Thoracoscopic talc poudrage decreases T-lymphocytes in the peripheral blood. <i>Respiratory Medicine</i> , 2007, 101, 1212-1217.	2.9	3
114	Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. <i>Nature Medicine</i> , 2006, 12, 846-851.	30.7	196
115	No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. <i>Leukemia Research</i> , 2006, 30, 240-241.	0.8	56
116	Amifostine Stimulates the Formation of Hematopoietic Bone Marrow Progenitors from B-Cell Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 2004, 112, 136-140.	1.4	2
117	Splenectomy for Massive Splenic Infarction Unmasks Paroxysmal Nocturnal Hemoglobinuria. <i>Acta Haematologica</i> , 2003, 110, 193-196.	1.4	8
118	Successful Treatment of Angioimmunoblastic Lymphadenopathy with Dysproteinemia-Type T-Cell Lymphoma with Fludarabine. <i>Acta Haematologica</i> , 2001, 105, 106-108.	1.4	15